• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原研和生物类似物促红细胞生成素产品的质量及批次间一致性

Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.

作者信息

Halim Liem Andhyk, Brinks Vera, Jiskoot Wim, Romeijn Stefan, Haselberg Rob, Burns Chris, Wadhwa Meenu, Schellekens Huub

机构信息

Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG Utrecht, the Netherlands.

Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA Leiden, the Netherlands.

出版信息

J Pharm Sci. 2016 Feb;105(2):542-550. doi: 10.1016/j.xphs.2015.10.019. Epub 2016 Jan 9.

DOI:10.1016/j.xphs.2015.10.019
PMID:26869417
Abstract

Comprehensive physicochemical characterization and biological assays are essential parts in assessing quality attributes of biologicals. Here, we compared the quality of different marketed recombinant human erythropoietin (epoetin) products: originators, Eprex and NeoRecormon as well as 2 biosimilars, Retacrit and Binocrit. In addition, assessment of batch-to-batch variability was included by collecting 2 or more batches of each product. Common assays which included sodium dodecyl sulfate-polyacrylamide gel electrophoresis, high-performance size-exclusion chromatography, asymmetrical flow field-flow fractionation, capillary zone electrophoresis, and potency testing were used. Of the tested products and among batches of single products, variations in epoetin content, isoform profiles, and potency were found. Ultimately, this study demonstrated the high quality of epoetin products with some degree of variation among products and batches, confirming the "similar but not identical" paradigm of biologicals.

摘要

全面的物理化学表征和生物学测定是评估生物制品质量属性的重要组成部分。在此,我们比较了不同市售重组人促红细胞生成素(促红素)产品的质量:原研产品益比奥和宁红欣,以及两种生物类似药罗可曼和倍怡。此外,通过收集每种产品的两批或更多批次产品来评估批次间的变异性。采用了包括十二烷基硫酸钠-聚丙烯酰胺凝胶电泳、高效尺寸排阻色谱、不对称流场-流分级、毛细管区带电泳和效价检测在内的常规测定方法。在所测试的产品以及单个产品的批次之间,发现促红素含量、异构体谱和效价存在差异。最终,本研究证明了促红素产品质量较高,但产品和批次之间存在一定程度的差异,证实了生物制品“相似但不相同”的范式。

相似文献

1
Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.原研和生物类似物促红细胞生成素产品的质量及批次间一致性
J Pharm Sci. 2016 Feb;105(2):542-550. doi: 10.1016/j.xphs.2015.10.019. Epub 2016 Jan 9.
2
Quality of original and biosimilar epoetin products.原研和生物类似物重组人促红素产品的质量。
Pharm Res. 2011 Feb;28(2):386-93. doi: 10.1007/s11095-010-0288-2. Epub 2010 Oct 1.
3
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.一种市售的和两种欧洲市售的促红细胞生成素阿尔法的药代动力学和药效学特征比较:一项随机前瞻性研究。
Drugs R D. 2011;11(1):61-75. doi: 10.2165/11588270-000000000-00000.
4
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.生物类似药结构与功能评估的综合方法:对促红细胞生成素的启示
BioDrugs. 2015 Aug;29(4):285-300. doi: 10.1007/s40259-015-0136-3.
5
Analytical platform for glycomic characterization of recombinant erythropoietin biotherapeutics and biosimilars by MS.通过质谱对重组促红细胞生成素生物治疗药物和生物类似药进行糖组学表征的分析平台。
Bioanalysis. 2013 Mar;5(5):545-59. doi: 10.4155/bio.12.327.
6
Clinical safety of biosimilar recombinant human erythropoietins.生物类似重组人红细胞生成素的临床安全性。
Expert Opin Drug Saf. 2012 Sep;11(5):819-40. doi: 10.1517/14740338.2012.712681. Epub 2012 Aug 13.
7
Safety and biosimilarity of ior(®) EPOCIM compared with Eprex(®) based on toxicologic, pharmacodynamic, and pharmacokinetic studies in the Sprague-Dawley rat.基于对斯普拉格-道利大鼠的毒理学、药效学和药代动力学研究,比较ior(®) EPOCIM与Eprex(®)的安全性和生物相似性。
J Pharm Sci. 2014 Nov;103(11):3432-3441. doi: 10.1002/jps.24164. Epub 2014 Sep 22.
8
Glycan analysis of erythropoiesis-stimulating agents.糖基分析促红细胞生成素。
J Pharm Biomed Anal. 2020 Feb 20;180:113031. doi: 10.1016/j.jpba.2019.113031. Epub 2019 Dec 5.
9
Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application.静脉应用后生物类似依泊汀kappa 和其他重组促红细胞生成素的兴奋剂检测控制。
Drug Test Anal. 2011 Nov-Dec;3(11-12):798-805. doi: 10.1002/dta.369. Epub 2011 Oct 19.
10
Optimization and qualification of capillary zone electrophoresis method for glycoprotein isoform distribution of erythropoietin for quality control laboratory.用于质量控制实验室的促红细胞生成素糖蛋白异构体分布的毛细管区带电泳方法的优化与验证
J Pharm Biomed Anal. 2009 Oct 15;50(3):538-43. doi: 10.1016/j.jpba.2009.05.007. Epub 2009 May 19.

引用本文的文献

1
Satisfying QTPP of Erythropoietin Biosimilar by QbD through DoE-Derived Downstream Process Engineering.通过基于设计空间的下游工艺工程实现质量源于设计的促红细胞生成素生物类似药的质量目标产品概况
Pharmaceutics. 2023 Aug 4;15(8):2087. doi: 10.3390/pharmaceutics15082087.
2
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.SB4 和 SB2、依那西普和英夫利昔单抗生物类似药的批间一致性。
BioDrugs. 2020 Apr;34(2):225-233. doi: 10.1007/s40259-019-00402-0.
3
The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond.
美国的生物类似药途径:对创新型公司和生物类似药公司视角的分析及其他方面。
J Food Drug Anal. 2019 Jul;27(3):671-678. doi: 10.1016/j.jfda.2019.03.003. Epub 2019 Apr 30.
4
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?促红素生物类似药治疗肾性贫血:从十年的欧洲经验中我们学到了什么?
Clin Drug Investig. 2018 Jun;38(6):481-490. doi: 10.1007/s40261-018-0637-1.
5
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.促红素类生物仿制药治疗化疗引起的贫血:10 年经验总结
BioDrugs. 2018 Apr;32(2):129-135. doi: 10.1007/s40259-018-0262-9.
6
Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.比较生物类似药与原研药的安全性信息:欧洲风险管理计划的横断面分析。
Br J Clin Pharmacol. 2018 Apr;84(4):738-763. doi: 10.1111/bcp.13454. Epub 2018 Jan 18.
7
Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.在真实环境中转换为红细胞生成刺激剂(ESA)生物类似药与维持 ESA 原研药的疗效比较:血液透析患者的匹配对照研究。
Clin Drug Investig. 2017 Oct;37(10):965-973. doi: 10.1007/s40261-017-0562-8.